Dalvotoclax
Dalvotoclax (Example 8) is a selective inhibitor of BCL-2. Dalvotoclax has good liver microsomal stability. Dalvotoclax inhibits the activity of anti-apoptotic BCL-2 protein and anti-apoptotic BCL-XL protein. Dalvotoclax can be studied in research for B cell leukemia[1].
Product Specifications
CAS Number
[2416927-21-2]
UNSPSC
12352005
Target
Bcl-2 Family
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
O=C(C(C=CC(N1CCN(CC(CCC(C)(C2)C)=C2C3=C(Cl)C=C(C(F)(F)F)C=C3)CC1)=C4)=C4OC5=CN=C6NC=CC6=C5)NS(C7=CC([N+]([O-])=O)=C(NC[C@H]8COCCO8)C=C7)(=O)=O
Molecular Formula
C45H47ClF3N7O8S
Molecular Weight
938.41
References & Citations
[1]Fei Liu, et al., Trifluoromethyl-substituted sulfonamide as bcl-2-selective inhibitor. WO2020088442A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Lentiviral human FAM3A shRNA (UAS) - Lentiviral human FAM3A shRNA (UAS, GFP) (100)
